Biopharma Informatic | McAllen, TX

Research site

(Unclaimed)

Location

1200 E. Ridge Rd. Suite 4, McAllen, Texas, United States of America

Site insights

Top conditions

Top treatments

LY3537031

Brenipatide

Tirzepatide

Vonoprazan

NNC0487-0111

Survodutide

Deudomperidone

Finerenone

Cilofexor

CIN-102

Parent organization

This site is a part of Biopharma Informatic

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

12 of 21 total trials

A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

The main purpose of the SYNERGY-OUTCOMES study is to find out whether retatrutide and tirzepatide can prevent major adverse liver outcomes (MALO) in...

Enrolling

Metabolic Dysfunction-Associated Steatotic Liver Disease

Drug: Tirzepatide

Drug: Placebo

A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity (HF-POLARIS)

This study is being done to look at the safety and effect of NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction (HFpEF) or He...

Enrolling

Obesity

Heart Failure

Drug: NNC0487-0111

Drug: Placebo

A Study in Adult Participants With EoE to Evaluate Vonoprazan 20 mg Compared to Placebo After 12 Weeks and to Evaluate Vonoprazan 20 mg Up to 24 Weeks

The primary objective of this study is to assess the efficacy of vonoprazan 20 mg once daily (QD) compared to placebo QD in the number of participant...

Active, not recruiting

Eosinophilic Esophagitis

Drug: Placebo

Drug: Vonoprazan

A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Constipation (IBS-C) (RENEW-IBS-C)

The purpose of this study is to evaluate how well brenipatide (LY3537031) is tolerated what side effects may occur, and the safety and efficacy in pa...

Enrolling

Irritable Bowel Syndrome

Constipation

Drug: LY3537031

Drug: Placebo

A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Diarrhea (IBS-D) (RENEW-IBS-D)

The purpose of this study is to evaluate how well brenipatide (LY3537031) is tolerated, what side effects may occur, and the safety and efficacy in p...

Enrolling

Irritable Bowel Syndrome

Diarrhea

Drug: LY3537031

Drug: Placebo

A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity (SURMOUNT-MMO)

This study will investigate the effect of tirzepatide on the reduction of morbidity and mortality in adults living with obesity and provide additiona...

Active, not recruiting

Overweight

Obesity

Drug: Placebo

Drug: Tirzepatide

A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease (VitaliThy)

The main purpose of this study is to look at how efgartigimod affects thyroid function in adults with Graves' Disease (GD). The study will also check...

Enrolling

Graves Disease

Graves' Disease

Biological: Efgartigimod PH20 SC

Other: Placebo PH20 SC

A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

The purpose of this study is to evaluate the efficacy of lepodisiran in reducing cardiovascular risk in participants with high lipoprotein(a) who hav...

Active, not recruiting

Atherosclerotic Cardiovascular Disease (ASCVD)

Elevated Lp(a)

Drug: Lepodisiran Sodium

Drug: Placebo

Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a) (MOVE-Lp(a))

The purpose of this study is to evaluate the efficacy of muvalaplin in reducing cardiovascular risk in participants with high lipoprotein(a) who have...

Enrolling

Atherosclerotic Cardiovascular Disease (ASCVD)

Elevated Lp(a)

Drug: Placebo

Drug: Muvalaplin

EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)/Ritonavir in Patients Under 18 Years of Age With COVID-19 That Are Not Hospitalized But Are at Risk for Severe Disease

The purpose of this clinical trial is to learn about the safety, pharmacokinetics (pharmacokinetics helps us understand how the drug is changed and e...

Enrolling

COVID-19

Drug: nirmatrelvir

Drug: ritonavir

LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

This study is open to adults who are at least 18 years old and have:* A confirmed liver disease called non-alcoholic steatohepatitis (NASH) or* A con...

Enrolling

Metabolic Dysfunction Associated Steatohepatitis

Combination Product: Survodutide

Combination Product: Placebo matching survodutide

LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

This study is open to adults who are at least 18 years old living with obesity and have:* a confirmed liver disease called non-alcoholic steatohepati...

Enrolling

Metabolic Dysfunction Associated Steatohepatitis (MASH)

Liver Fibrosis

Combination Product: Placebo

Combination Product: Survodutide